Celldex Therapeutics, Inc.
CLDX
$21.75
-$0.18-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -199.61M | -178.85M | -157.86M | -154.08M | -150.22M |
| Total Depreciation and Amortization | 3.35M | 3.27M | 3.18M | 3.12M | 3.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.27M | 21.67M | 18.51M | 17.12M | 17.32M |
| Change in Net Operating Assets | -16.20M | -17.60M | -21.60M | -24.00M | 8.30M |
| Cash from Operations | -186.19M | -171.51M | -157.78M | -157.84M | -121.49M |
| Capital Expenditure | -2.29M | -1.84M | -1.92M | -1.83M | -1.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 166.90M | 69.87M | -288.21M | -483.51M | -520.01M |
| Cash from Investing | 164.61M | 68.03M | -290.13M | -485.34M | -521.45M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.89M | 5.54M | 441.45M | 658.44M | 657.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.89M | 5.54M | 441.45M | 658.44M | 657.46M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.70M | -97.94M | -6.46M | 15.27M | 14.52M |